This report on the organ transplant immunosuppressant drugs market studies the current and future prospects of the global market. Organ transplant immunosuppressant drugs market are prescribed to patients during or after transplant of organs such as kidney, liver, heart, lung and bone marrow. Organ dysfunction caused due to severe injuries, cancer, organ failure and/or genetic disorders necessitate the requirement for organ transplant procedures. Thus, rise in the number of organ transplants across the globe, along with advancements in the immunosuppressant drugs are expected to propel the global organ transplant immunosuppressant drugs market.
The organ transplant immunosuppressant drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global organ transplant immunosuppressant drugs market with respect to the segments based on the type of drug class, transplant, and their geographic analysis. A detailed qualitative analysis of driving and restraining factors for the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global intracranial pressure monitors market.
Based on drug class, the organ transplant immunosuppressant drugs market has been segmented into four major categories: calcineurin inhibitors, antiproliferative agents, mTOR inhibotrs, antibodies and steroids. On the basis of transplant type, the market has been categorized into five segments: kidney, bone marrow, liver, heart, lungs, and others (intestinal and multi-visceral organs). The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of USD million for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.
Geographically, the global organ transplant immunosuppressant drugs market has been categorized into four major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, Rest of Europe), Asia Pacific (Japan, Australia, Rest of Asia Pacific), Latin America (Brazil, Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.
The report also profiles major players in the global organ transplant immunosuppressant drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AbbVie, Inc., Astellas Pharma, Inc., Bristol?Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genzyme Corporation (Sanofi S.A.), GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc. and Veloxis Pharmaceuticals A/S.
The global organ transplant immunosuppressant drugs market is segmented as follows:
Global Organ Transplant Immunosuppressant Drugs, by Drug Class
Global Organ Transplant Immunosuppressant Drugs, by Transplant
Global Organ Transplant Immunosuppressant Drugs, by Geography
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote